軽度認知障害:治療薬開発パイプライン分析

◆英語タイトル:Mild Cognitive Impairment - Pipeline Review, H2 2017
◆商品コード:GMDHC9706IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2017年9月12日
◆ページ数:113
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥214,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥642,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における軽度認知障害の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・軽度認知障害の概要
・軽度認知障害治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・軽度認知障害パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・軽度認知障害治療薬開発に取り組んでいる企業:企業別製品パイプライン
・軽度認知障害治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Mild Cognitive Impairment – Pipeline Review, H2 2017

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment – Pipeline Review, H2 2017, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline landscape.

Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety and apathy. Risk factors include diabetes, high blood pressure, and depression, smoking and elevated cholesterol.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Mild Cognitive Impairment – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Mild Cognitive Impairment (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 8, 6, 1, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 2 and 1 molecules, respectively.

Mild Cognitive Impairment (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Mild Cognitive Impairment (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Mild Cognitive Impairment (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Mild Cognitive Impairment (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Mild Cognitive Impairment (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Mild Cognitive Impairment – Overview
Mild Cognitive Impairment – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Mild Cognitive Impairment – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Mild Cognitive Impairment – Companies Involved in Therapeutics Development
AgeneBio Inc
Avraham Pharmaceuticals Ltd
CereSpir Inc
ConSynance Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Company
Ensol Biosciences Inc
Genzyme Corp
IntelGenx Corp
Krenitsky Pharmaceuticals Inc
Merck & Co Inc
Nanotherapeutics Inc
Neuron Biopharma SA
Pfizer Inc
Sage Therapeutics Inc
SBI Pharmaceuticals Co Ltd
Suven Life Sciences Ltd
Takeda Pharmaceutical Company Ltd
Therapix Biosciences Ltd
Mild Cognitive Impairment – Drug Profiles
aminolevulinic acid hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAN-2401 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bosutinib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brexanolone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSP-1103 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSTI-200 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DAOI-B – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dronabinol – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elenbecestat – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-544 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ladostigil tartrate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levetiracetam ER – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levofacetoperane – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3002813 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3303560 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
montelukast – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Moriah-1000 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPS-0158 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPS-0163 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NST-0037 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NST-0076 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NST-0078 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NTC-942 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAM-38 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Agonize Insulin Receptor for Mild Cognitive Impairment and Alzheimer’s Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sargramostim – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GABRA5 Receptor for CNS Disorders – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVN-501 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVN-507 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVN-512 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVNI-1307014 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVNI-1312004 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-071 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tropisetron – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
verubecestat – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mild Cognitive Impairment – Dormant Projects
Mild Cognitive Impairment – Discontinued Products
Mild Cognitive Impairment – Product Development Milestones
Featured News & Press Releases
Aug 22, 2016: IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the Brain
Jul 13, 2016: IntelGenx to Initiate Phase 1 Trial of Montelukast
Jul 28, 2015: Avraham Pharmaceuticals Announces Successful Second Interim Results in Phase 2b Study of Ladostigil for the Treatment of Mild Cognitive Impairment
Jul 14, 2015: CereSpir Obtains New Patent From USPTO Covering the Optimal Synthetic Route for Commercial Manufacture of CSP-1103 in Late Stage Development to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer’s Disease
Jul 01, 2015: CereSpir Submits Special Protocol Assessment Request to FDA for a Phase 3 Clinical Trial to Test the Ability of CSP-1103 to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer’s Disease
Jul 08, 2014: Avraham Pharmaceuticals Announces Successful Interim Results in Phase 2b Study of Ladostigil for the Treatment of MCI
Jul 26, 2013: CERESPIR INCORPORATED IS PLEASED WITH POSITIVE INTERIM PHASE 2 RESULTS FOR CHF 5074 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT, PRESENTED BY CHIESI AT THE AAIC 2013 MEETING IN BOSTON
May 17, 2012: Avraham Initiates Phase II Ladostigil Study For Treatment Of Mild Cognitive Impairment
Apr 14, 2010: Alzheimer Drug Co Avraham Pharmaceuticals Raises $9m
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Mild Cognitive Impairment, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Mild Cognitive Impairment - Pipeline by AgeneBio Inc, H2 2017
Mild Cognitive Impairment - Pipeline by Avraham Pharmaceuticals Ltd, H2 2017
Mild Cognitive Impairment - Pipeline by CereSpir Inc, H2 2017
Mild Cognitive Impairment - Pipeline by ConSynance Therapeutics Inc, H2 2017
Mild Cognitive Impairment - Pipeline by Eisai Co Ltd, H2 2017
Mild Cognitive Impairment - Pipeline by Eli Lilly and Company, H2 2017
Mild Cognitive Impairment - Pipeline by Ensol Biosciences Inc, H2 2017
Mild Cognitive Impairment - Pipeline by Genzyme Corp, H2 2017
Mild Cognitive Impairment - Pipeline by IntelGenx Corp, H2 2017
Mild Cognitive Impairment - Pipeline by Krenitsky Pharmaceuticals Inc, H2 2017
Mild Cognitive Impairment - Pipeline by Merck & Co Inc, H2 2017
Mild Cognitive Impairment - Pipeline by Nanotherapeutics Inc, H2 2017
Mild Cognitive Impairment - Pipeline by Neuron Biopharma SA, H2 2017
Mild Cognitive Impairment - Pipeline by Pfizer Inc, H2 2017
Mild Cognitive Impairment - Pipeline by Sage Therapeutics Inc, H2 2017
Mild Cognitive Impairment - Pipeline by SBI Pharmaceuticals Co Ltd, H2 2017
Mild Cognitive Impairment - Pipeline by Suven Life Sciences Ltd, H2 2017
Mild Cognitive Impairment - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
Mild Cognitive Impairment - Pipeline by Therapix Biosciences Ltd, H2 2017
Mild Cognitive Impairment - Dormant Projects, H2 2017
Mild Cognitive Impairment - Dormant Projects, H2 2017 (Contd..1), H2 2017
Mild Cognitive Impairment - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Mild Cognitive Impairment, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

【レポートのキーワード】

軽度認知障害

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[軽度認知障害:治療薬開発パイプライン分析]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆